Navigation Links
Amicus Therapeutics Announces Plan to Initiate Phase 1 Study of AT2220 for Pompe Disease
Date:9/30/2009

CRANBURY, N.J., Sept. 30 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced it plans to initiate a Phase 1 study of AT2220 (1-deoxynojirimycin HCl), its investigational drug in development for the treatment of Pompe Disease. The primary objective of this study is to evaluate the pharmacokinetics of AT2220 in muscle tissue in healthy adult subjects. The U.S. Food and Drug Administration (FDA) has agreed to Amicus' proposal for the Phase 1 study and subsequently converted the clinical hold of AT2220 to a partial hold to allow the conduct of this study.

In June 2008, the Company announced the commencement of a Phase 2 clinical trial of AT2220 in adults with Pompe disease based on data from both preclinical and Phase 1 studies. In February 2009, the Company announced it had suspended enrollment after two patients enrolled in the trial experienced serious adverse events that were probably related to treatment with AT2220. The AT2220 Investigational New Drug application (IND) was subsequently placed on clinical hold by the FDA.

The Company has completed a thorough evaluation of all data from these two subjects and has completed additional preclinical studies of AT2220. Based on these data, the Company proposed the planned Phase 1 study to FDA in order to further evaluate the pharmacokinetics of AT2220 in muscle, the key target tissue in Pompe disease. This study will be an open label, single dose study and will commence in the fourth quarter of this year. The Company expects data from this trial to be available in the first quarter of 2010. Based on the results of this study, the Company will determine the appropriate next steps for the program working in close collaboration with the FDA.

One of the recently completed preclinical studies evaluated the effects of various doses and regimen
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... ST. LOUIS , Sept. 18, 2014 /PRNewswire/ ... ) announced today it has entered into a ... Michigan (U-M) Medical School,s Vector Core. Under the ... Sigma CRISPR technology, experimental design consultation, and dedicated ... poised to accelerate gene editing-based research at the ...
(Date:9/18/2014)... loss and diabetes prevention, could actually hasten the development ... it in a surprising way: by changing the composition ... population of bacteria residing in our intestines. These findings, ... published today in Nature . Among other things, ... Department, who led this research together with Prof. Eran ...
(Date:9/18/2014)... CA (PRWEB) September 18, 2014 ... which include Sartorius/Biohit, Socorex, Capp, and AccuPet brand ... volumes of 100 uL or less and are ... and forensic applications. , The micropipette promotions ... quality and economic alternative products to help customers ...
(Date:9/17/2014)... Sept. 17, 2014 The global consumption of squalene ... Squalene is a natural skin-identical chemical that finds applications in ... food supplements, pharmaceuticals, and in other applications like high grade ... has a few major players and is regionally segregated. Sophim ... Liver Oil Co. Ltd. ( Japan ), SeaDragon ...
Breaking Biology Technology:Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 2Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 3Sigma-Aldrich, University of Michigan Medical School Establish CRISPR Core Lab Partnership 4Gut bacteria, artificial sweeteners and glucose intolerance 2Gut bacteria, artificial sweeteners and glucose intolerance 3Major Pipette Distributor Pipette.com Announces Promotions on Sartorius/Biohit, Socorex, Capp, and AccuPet Micropipettes 2Major Pipette Distributor Pipette.com Announces Promotions on Sartorius/Biohit, Socorex, Capp, and AccuPet Micropipettes 3Squalene Market by Source (Animal & Vegetable) & by End-user Industry (Cosmetics, Pharmaceuticals & Food Industry) - Global Trends & Forecasts to 2019 2Squalene Market by Source (Animal & Vegetable) & by End-user Industry (Cosmetics, Pharmaceuticals & Food Industry) - Global Trends & Forecasts to 2019 3
... generation design reduces the amount of retraction needed for surgical ... ... 23 Pioneer Surgical Technology,today announces the market availability of the ... cervical fusion procedures while addressing the clinical needs of,anterior cervical discectomy ...
... Technology,Inc. (Nasdaq: EFUT ) (,eFuture,), a leading ... to China,s retail and consumer goods,industries, today announced ... its,mySHOP Retail Business Management System 3.0 (,mySHOP 3.0, ... Group,). eFuture will install,the system at Tiens Group,s ...
... company enters into a strategic supply chain agreement in preparation for ... ... July 23, 2008 -- CN Probes , an emerging nanotech ... (contract manufacturer). This agreement puts CN Probes closer to ramping up ...
Cached Biology Technology:Pioneer(R) Surgical Technology, Inc. Announces the Market Launch of the SlimFuse(TM) Anterior Cervical Plate System 2eFuture Signs Contract to Provide Tiens Group with Retail Business Management System 2eFuture Signs Contract to Provide Tiens Group with Retail Business Management System 3eFuture Signs Contract to Provide Tiens Group with Retail Business Management System 4eFuture Signs Contract to Provide Tiens Group with Retail Business Management System 5Carbon Nanoprobes, Inc Announces Production Agreement With Leading MEMS Foundry 2Carbon Nanoprobes, Inc Announces Production Agreement With Leading MEMS Foundry 3
(Date:9/17/2014)... September 17, 2014 Researchers at UTSouthwestern Medical Center ... circulating protein apolipoprotein E, called apoE3, helps repair the ... apoE4, do not get the benefit of this repair, ... "We believe that we have identified one mechanism by ... a genetic variant, apoE4, is detrimental," said Dr. ...
(Date:9/17/2014)... University] After decades of decline, grasses have returned ... the eye, the marsh in those places seems healthy ... key service of the marsh coastal protection ... the ecosystem function hasn,t come back," said ecologist Mark ... of the study in the journal Biological Conservation ...
(Date:9/17/2014)... the United Kingdom forms a new crime unit designed ... uproar last year over horse meat being passed off ... technique for detecting meat adulteration. They describe their approach, ... ACS, Journal of Agricultural and Food Chemistry . ... is a major global economic problem. But they also ...
Breaking Biology News(10 mins):Protein variant may boost cardiovascular risk by hindering blood vessel repair 2Cape Cod saltmarsh recovery looks good, falls short 2Cape Cod saltmarsh recovery looks good, falls short 3
... issue of the Journal of General Physiology ... of British Columbia, Vancouver) and colleagues that explores pore ... in vivo nonsense suppression technology. The study will be ... to Riccardo Olcese (UCLA) in a commentary accompanying the ...
... in DNA sequencing make determining how living things ... which their genes have been rearranged on chromosomes. ... requires massive computing impossible even on the most ... $1 million project, funded by the National Science ...
... in high-throughput DNA sequencing have opened up the ... by analyzing the ways in which their genes ... evolutionary relationships from rearrangement events is computationally intensive ... today. Research recently funded by the American ...
Cached Biology News:Petascale computational tools could revolutionize understanding of genomic evolution 2Petascale computing tools could provide deeper insight into genomic evolution 2Petascale computing tools could provide deeper insight into genomic evolution 3
... Normal;heading 1;heading ... types and experimental ... for standard transfection ... transduction systems. ViraPower ...
... Product Rabbit polyclonal to ... conjugated to KLH, corresponding to amino ... / Specificity Cross-reacts with Rat.Expected to ... Mouse (100% identity with immunogen), Rabbit (100% ...
RayBio Human Angiogenesis Antibody Array 2.1 (8 array membranes) with Accessory, detects 23 angiogenic factors (for lysate) Class: Antibody Array Products Product Group: Antibody Array...
... Inventory Racks for cryogenic vials. ... cardboard or stainless steel boxes ... cryo vials. Vapor phase ... Platform risers to be ...
Biology Products: